SIDLEY

SIDLEY AUSTIN LLP 555 CALIFORNIA STREET SUITE 2000 SAN FRANCISCO, CA 94104 +1 415 772 1200 +1 415 772 7400 FAX

AMERICA • ASIA PACIFIC • EUROPE

VIA EDGAR

May 24, 2024

United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Lauren Nguyen

Re: Biodesix, Inc. Registration Statement on Form S-1 Filed April 23, 2024 File No. 333-278881

Ladies and Gentlemen:

On behalf of our client, Biodesix, Inc. (the "<u>Company</u>"), we hereby submit this letter in response to comments from the staff (the "<u>Staff</u>") of the Securities and Exchange Commission (the "<u>Commission</u>") contained in its letter dated May 17, 2024 (the "<u>Comment Letter</u>"), relating to the above referenced Registration Statement on Form S-1 filed with the Commission (the "<u>Registration Statement</u>"). We are concurrently filing via EDGAR this letter and an amendment to the Registration Statement on Form S-1 ("<u>Amendment No. 1</u>").

In this letter, we have recited the comments from the Staff in italicized, bold type and have followed each comment with the Company's response in ordinary type.

Form S-1 filed on April 23, 2024

General

1. We note your disclosure on page 153 that your selling securityholders may sell their securities through one or more underwritten offerings on a firm commitment or best efforts basis. Please confirm your understanding that the retention by a selling stockholder of an underwriter would constitute a material change to your plan of distribution requiring a post-effective amendment. Refer to your undertaking provided pursuant to Item 512(a)(1)(iii) of Regulation S-K.

In response to the Staff's comment, the Company has revised the Registration Statement to confirm the Company's understanding that the retention by a selling stockholder of an underwritten offering

on a firm commitment or best efforts basis would constitute a material change to the Company's plan of distribution requiring a post-effective amendment.

* * * *

If you have questions with respect to Amendment No. 1 or the responses set forth above, please direct the questions to me at (415) 772-1256 or frahmani@sidley.com.

Sincerely,

/s/ Frank Rahmani

Frank Rahmani

cc: Scott Hutton, Biodesix, Inc. Robin Harper Cowie, Biodesix, Inc. Chris Vazquez, Biodesix, Inc. Samir A. Gandhi, Sidley Austin LLP